Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
X-ray Diffraction of Biological Samples01:10

X-ray Diffraction of Biological Samples

X-ray diffraction or XRD is an analytical tool that utilizes X-rays to study ordered structures such as crystalline organic and inorganic samples, polycrystalline materials, proteins, carbohydrates, and drugs.
According to Bragg's law, when X-rays strike the sample positioned on a stage, the rays are  scattered by the electron clouds around the sample atoms. The  X-ray diffraction or scattering is caused by constructive interference of the X-ray waves that reflect off the internal crystal...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial.

Pharmacogenomics·2026
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026

Related Experiment Video

Updated: Jul 6, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

DxS Ltd.

Joanne Cross1

  • 1DxS Ltd, 48 Grafton Street, Manchester, M13 9XX, UK. Joanne.cross@dxsdiagnostics.com

Pharmacogenomics
|April 4, 2008
PubMed
Summary
This summary is machine-generated.

DxS provides essential biomarker and companion diagnostic tools for cancer therapy development. Their validated assays identify patient mutations, enabling personalized medicine and supporting drug regulatory approval.

More Related Videos

Online Size-exclusion and Ion-exchange Chromatography on a SAXS Beamline
11:09

Online Size-exclusion and Ion-exchange Chromatography on a SAXS Beamline

Published on: January 5, 2017

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Related Experiment Videos

Last Updated: Jul 6, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

Online Size-exclusion and Ion-exchange Chromatography on a SAXS Beamline
11:09

Online Size-exclusion and Ion-exchange Chromatography on a SAXS Beamline

Published on: January 5, 2017

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Area of Science:

  • Oncology
  • Personalized Medicine
  • Biomarker Discovery

Background:

  • Personalized medicine requires validated biomarkers and companion diagnostics.
  • Pharmaceutical companies need tools to identify patient populations likely to respond to therapies.
  • Companion diagnostics aid clinicians in selecting targeted cancer treatments.

Purpose of the Study:

  • To present DxS's role in providing biomarker and companion diagnostic solutions.
  • To highlight the utility of DxS products in clinical trials and therapy selection.
  • To showcase the development of novel diagnostic kits for cancer therapy support.

Main Methods:

  • Development and validation of biomarker assays for key oncogenes.
  • Commercialization of CE-marked diagnostic kits (TheraScreen) for specific gene mutations (EGFR, K-RAS).
  • Partnership with pharmaceutical companies to support drug development and regulatory processes.

Main Results:

  • Launched the first companion diagnostic for colorectal cancer therapy (Vectibix).
  • DxS kits detect oncogene mutations correlating with drug response.
  • Validated biomarker kits are available for research on multiple genes (EGFR, RAS, RAF, BCR-ABL).

Conclusions:

  • DxS offers critical tools for personalized cancer medicine.
  • Validated biomarker assays and companion diagnostics accelerate drug development and improve patient treatment selection.
  • The company plays a key role in advancing targeted cancer therapies through diagnostics.